John Bruning

John Bruning

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2011 in Nature
Verified
Journal Article
Open access
PDF file
JCJang Hyun Choi
Jang Hyun Choi
ABAlex Banks
Alex Banks
TKTheodore M. Kamenecka
Theodore M. Kamenecka
SBScott A. Busby
Scott A. Busby
MCMichael J. Chalmers
Michael J. Chalmers
PGPatrick R. Griffin
Patrick R. Griffin
The nuclear receptor PPARγ is the target of thiazolidinedione antidiabetics including rosiglitazone and pioglitazone. These full PPARγ agonists are effective and well tolerated in most patients, but cause fluid retention and weight gain in a minority. In this proof-of-concept study, Choi et al. show the development of specific PPARγ ligands that retain antidiabetic activity through blockade of Cdk5-mediated PPARγ phosphorylation, but that are not full PPARγ agonists. In mouse models, these ligands do not cause the side effects sometimes associated with full PPARγ agonists. PPARγ is the functioning receptor for the thiazolidinedione (TZD) class of antidiabetes drugs including rosiglitazone and pioglitazone1. These drugs are full classical agonists for this nuclear receptor, but recent data have shown that many PPARγ-based drugs have a separate biochemical activity, blocking the obesity-linked phosphorylation of PPARγ by Cdk5 (ref. 2). Here we describe novel synthetic compounds that have a unique mode of binding to PPARγ, completely lack classical transcriptional agonism and block the Cdk5-mediated phosphorylation in cultured adipocytes and in insulin-resistant mice. Moreover, one such compound, SR1664, has potent antidiabetic activity while not causing the fluid retention and weight gain that are serious side effects of many of the PPARγ drugs. Unlike TZDs, SR1664 also does not interfere with bone formation in culture. These data illustrate that new classes of antidiabetes drugs can be developed by specifically targeting the Cdk5-mediated phosphorylation of PPARγ.

1 October 2007 in Structure
Verified
Journal Article
Closed access
JBJohn Bruning
John Bruning
MCMichael J. Chalmers
Michael J. Chalmers
SPSwati Prasad
Swati Prasad
SBScott A. Busby
Scott A. Busby
TKTheodore M. Kamenecka
Theodore M. Kamenecka
PGPatrick R. Griffin
Patrick R. Griffin

8 September 2015 in PPAR Research
Verified
Journal Article
Open access
PDF file
AKAlice J. Kroker
Alice J. Kroker
JBJohn Bruning
John Bruning
PPARγ(peroxisome proliferator activated receptorγ) is a ligand activated transcription factor of the nuclear receptor superfamily that controls the expression of a variety of genes involved in fatty acid metabolism, adipogenesis, and insulin sensitivity. While endogenous ligands of PPARγinclude fatty acids and eicosanoids, synthetic full agonists of the receptor, including members of the thiazolidinedione (TZD) class, have been widely prescribed for the treatment of type II diabetes mellitus (T2DM). Unfortunately, the use of full agonists has been hampered by harsh side effects with some removed from the market in many countries. In contrast, partial agonists of PPARγhave been shown to retain favourable insulin sensitizing effects while exhibiting little to no side effects and thus represent a new potential class of therapeutics for the treatment of T2DM. Partial agonists have been found to not only display differences in transcriptional and cellular outcomes, but also act through distinct structural and dynamic mechanisms within the ligand binding cavity compared to full agonists.


10 April 2011 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
JZJun Zhang
Jun Zhang
MCMichael J Chalmers
Michael J Chalmers
KSKeith R Stayrook
Keith R Stayrook
LBLorri L Burris
Lorri L Burris
YWYongjun Wang
Yongjun Wang
PGPatrick R Griffin
Patrick R Griffin
A comprehensive HDX analysis of the vitamin D receptor–retinoid X receptor (VDR-RXR) reveals extensive allosteric communication within the same polypeptide where DNA or ligand can induce alterations in distant domains of the receptors. The work also shows communication between subunits in the heterodimer. The vitamin D receptor (VDR) functions as an obligate heterodimer in complex with the retinoid X receptor (RXR). These nuclear receptors are multidomain proteins, and it is unclear how various domains interact with one another within the nuclear receptor heterodimer. Here, we show that binding of intact heterodimer to DNA alters the receptor dynamics in regions remote from the DNA-binding domains (DBDs), including the coactivator binding surfaces of both co-receptors, and that the sequence of the DNA response element can determine these dynamics. Furthermore, agonist binding to the heterodimer results in changes in the stability of the VDR DBD, indicating that the ligand itself may play a role in DNA recognition. These data suggest a mechanism by which nuclear receptors show promoter specificity and have differential effects on various target genes, providing insight into the function of selective nuclear receptor modulators.

16 March 2008 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
KNKendall W Nettles
Kendall W Nettles
JBJohn Bruning
John Bruning
GGGerman Gil
German Gil
JNJason Nowak
Jason Nowak
SSSanjay K Sharma
Sanjay K Sharma
GGGeoffrey Greene
Geoffrey Greene